Skip to main content
BROOKS LABORATORIES LIMITED logo

BROOKS LABORATORIES LIMITED — Investor Relations & Filings

Ticker · BROOKS ISIN · INE650L01011 LEI · 984500FY0879C7971B73 BSE.NS Manufacturing
Open in API
Filings indexed 490 across all filing types
Latest filing 2024-08-06 Regulatory Filings
Country IN India
Listing BSE.NS BROOKS

About BROOKS LABORATORIES LIMITED

https://www.brookslabs.net/

Brooks Laboratories Limited is a pharmaceutical manufacturing enterprise specializing in Contract Research and Manufacturing Services (CRAMS). The company focuses on the production of a diverse range of pharmaceutical formulations, including beta-lactam and non-beta-lactam products. Its portfolio encompasses various dosage forms such as dry powder injections, liquid injections, tablets, and capsules. Key therapeutic segments served include antibiotics, cardiovascular, gastrointestinal, and pain management. The company operates advanced manufacturing facilities designed to meet international quality standards, providing integrated solutions from formulation development to commercial-scale production. Brooks Laboratories emphasizes quality control and regulatory compliance to support its domestic and international client base.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing about an upcoming Board Meeting scheduled to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2024. It references regulatory compliance under SEBI Listing Obligations and Disclosure Requirements and insider trading regulations. The document does not contain the financial results themselves but is an announcement of the meeting where these results will be approved. The document length is short (2031 characters), and it serves as a notification rather than the actual financial report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement about an upcoming board meeting and financial results approval, not the financial report itself or a detailed interim report.
2024-08-06 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Ltd. regarding Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It confirms that Mr. Durga Shankar Maity has not been debarred from holding the office of Director by SEBI or any other authority. The content is a regulatory compliance update related to a director's status, not a full report or financial statement. The document length is short (1318 characters), and it serves as an official regulatory announcement rather than a detailed report or management information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-07-23 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming dematerialisation activities for the quarter ended 30th June 2024. It is a compliance certificate from the Registrar and Share Transfer Agent to the company and stock exchanges. The document is short (3202 characters) and primarily serves as a regulatory compliance confirmation rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or detailed financial data. It is not an announcement of a report but a certificate confirming regulatory compliance. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance certificates and miscellaneous regulatory documents.
2024-07-09 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing about the closure of the trading window pursuant to insider trading regulations. It mentions the trading window closure period related to the upcoming unaudited financial results for the quarter ended June 30, 2024, but does not contain any financial data or results itself. The document is short (1618 characters) and serves as an announcement rather than a report. It is not a financial report, earnings release, or management discussion. It is a regulatory compliance announcement related to insider trading restrictions. Therefore, it fits best under Regulatory Filings (RNS).
2024-06-26 English
Copy of Newspaper Publication
Regulatory Filings
2024-05-19 English
Financial Result Updates
Regulatory Filings
2024-05-18 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.